RARE Relative Valuation
RARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RARE is overvalued; if below, it's undervalued.
Historical Valuation
Ultragenyx Pharmaceutical Inc (RARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.04 is considered Undervalued compared with the five-year average of -10.43. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between 99.78 to 172.68 according to relative valuation methord. Compared to the current price of 27.31 USD , Ultragenyx Pharmaceutical Inc is Undervalued By 72.63%.
Relative Value
Fair Zone
99.78-172.68
Current Price：27.31
72.63%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
17.68
P/B
Median3y
20.36
Median5y
14.92
-14.34
FCF Yield
Median3y
-14.20
Median5y
-10.75
Competitors Valuation Multiple
The average P/S ratio for RARE's competitors is 47.75, providing a benchmark for relative valuation. Ultragenyx Pharmaceutical Inc Corp (RARE) exhibits a P/S ratio of 4.04, which is -91.53% above the industry average. Given its robust revenue growth of 27.99%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Ultragenyx Pharmaceutical Inc (RARE) currently overvalued or undervalued?
What is Ultragenyx Pharmaceutical Inc (RARE) fair value?
How does RARE's valuation metrics compare to the industry average?
What is the current P/B ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Jul 17 2025?
What is the current FCF Yield for Ultragenyx Pharmaceutical Inc (RARE) as of Jul 17 2025?
What is the current Forward P/E ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Jul 17 2025?